Galectin Therapeutics Inc.

NASDAQ:GALT

Biotechnology

Healthcare
$2.98 +1.62%

+$0.05 today

Market cap
$196.25M
Beta
0.49
P/E (TTM)
-7.1
EPS (TTM)
-$0.40
52W Low $1.85High $7.13

Volume 0.23M

Average 0.32M

GALT Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Galectin Therapeutics Inc.NASDAQ: GALT

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables outflow grows to $0

Q1 FY2026 accounts receivables was $0, compared with $0 a year earlier. Trailing-twelve-month accounts receivables was $0.

Context

  • Accounts receivables increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Accounts Receivables vs competitors

How GALT compares with its peers on the latest reported figures

  • GALT's LTM Mar 2026 accounts receivables of $0 is the 6th largest of the 10 companies compared; the peer median is $0.
GALT Competitors Peer median
Accounts Receivables for GALT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALTAltimmune, Inc.LTM Mar 2026$799K +2450.0%-14.5%2219.4%
QSIQuantum-Si incorporatedLTM Mar 2026$683K +174.7%—36.9%
ENGNenGene Holdings Inc.LTM Apr 2026$291K -142.7%——
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$205K ———
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$49.73K -134.1%——
GALTGalectin Therapeutics Inc.LTM Mar 2026$0 ———
DRTSAlpha Tau Medical Ltd.LTM Dec 2025$0 ———
AURAAura Biosciences, Inc.LTM Mar 2026$0 ———
DSGNDesign Therapeutics, Inc.LTM Mar 2026$0 ———
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$0 ———
Peer median (excluding GALT) $0+20.3%-14.5%1128.2%

Competitors are the stored peer set for GALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(30.53M)(38.78M)(41.07M)(47.05M)(30.84M)
Depreciation & Amortization41K32K33K37K53K
Deferred Income Tax00000
Stock-Based Compensation2.08M2.87M2.26M2.45M1.66M
Change in Working Capital3.75M4.97M4.68M2.28M609K
Accounts Receivables00000
Inventory00000
Accounts Payables3.69M4.24M2.67M(2.07M)(6.04M)
Other Working Capital65K724K2.01M4.36M6.65M
Other Non-Cash Items351K(147K)1.13M512K4.64M
Operating Cash Flow(24.31M)(31.06M)(32.97M)(41.77M)(23.88M)
Capital Expenditures00000
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow00000
Debt Repayment30M10M30M30M21M
Common Stock Issued6.81M001.23M5.48M
Common Stock Repurchased00000
Dividends Paid(171K)00(91K)0
Other Financing Activities171K010.03M91K0
Financing Cash Flow36.81M10M40.03M31.23M26.48M
Effect of Forex Changes00000
Net Change in Cash12.51M(21.06M)7.07M(10.54M)2.6M
Free Cash Flow(24.31M)(31.06M)(32.97M)(41.77M)(23.88M)

Galectin Therapeutics Inc.

NASDAQ:GALT

Intrinsic Alpha fair value

Locked

Current Price

$2.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.